Treatment trials in ankylosing spondylitis: Current and future considerations

Annals of the Rheumatic Diseases

Volumn 61, Issue SUPPL. 3, 2002, Pages

  Van der Heijde, D ^a   Braun, J ^b,c   McGonagle, D ^d   Siegel, J ^e  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RHEUMAZENTRUM RUHRGEBIET   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; CONFERENCE PAPER; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; JOINT FUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PHYSICAL DISABILITY; PHYSIOTHERAPY; PRIORITY JOURNAL; UNITED STATES; VISUAL ANALOG SCALE;

ACUTE-PHASE PROTEINS; ANTIRHEUMATIC AGENTS; CLINICAL TRIALS; HIP; HUMANS; JOINTS; MAGNETIC RESONANCE IMAGING; MOVEMENT; OUTCOME ASSESSMENT (HEALTH CARE); PAIN; SPINE; SPONDYLITIS, ANKYLOSING;

EID: 0036893308     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Bakker C, Boers M, van der Linden S. Mecisures to assess ankylosing spondylitis: Taxonomy, review, and recommendations. J Rheumatol 1993;20:1724-30.
2. van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 1997;24:2225-9.
3. van der Linden, van der Heijde DM. Ankylosing spondylitis and other B27 related spondylarthropathies. Baillieres Clin Rheumatol 1995;9:355-73.
4. van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in ankylosing spondylitis. J Rheumatol 1999;26:951-4.
5. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
6. van der Heijde DM, van der Linden S. Measures of outcome in ankylosing spondylitis and other spondyloarthritides. Baillieres Clin Rheumatol 1998;12:683-93.
7. OMERACT IV Conference. Cancun, Mexico. J Rheumatal Suppl, 1998.
8. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for outcome measures in rheumatology [editorial]. J Rheumatol 1998;25:198-9.
9. Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Outcome variables in ankylosing spondylitis: Evaluation of their relevance and discriminant capacity. J Rheumatol 1999;26:975-9.
10. Bellamy N. Musculoskeletal Clinical Metrology. Dordrecht: Kluwer, 1993:177-83.
11. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the bath ankylosing spondylitis functional index. J Rheumatol 1994;21;2281-5.
12. Dougados M, Gueguen A, Nakache JP, Ngueyn M, Mery C, Amor B. Evaluation of a functional index and articular index in ankylosing spondylitis. J Rheumatol 1988;15:302-7.
13. Ruof J, Stucki G. Comparison of the dougados functional index and the bath ankylosing spondylitis functional index. A literature review. J Rheumatol 1999;26:955-60.
14. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis disease activity index. J Rheumatol 1994;21:2286-91.
15. Kennedy LG, Jenkinson TR, Mallorie PA, Whitelock HC, Garrett SL, Calin A. Ankylosing spondylitis: The correlation between a new metrology score and radiology. Br J Rheumatol 1995;34:767-70.
16. Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987;46:197-202.
17. Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: A literature review. J Rheumatol 1999;26:966-70.
18. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999;26:980-4.
19. Ball J. The enthesopathy of ankylosing spondylitis. Br J Rheumatol 1983;22(suppl 2):25-8.
20. van der Heijde D, Spoonenberg A. Plain radiographs as an outcome measure in ankylosing spondylitis. J Rheumatol 1999;26:985-7.
21. Taylor HG, Wardle T, Beswick EJ, Dawes PT. The relationship of clinical and laboratory measurements to radiological change in ankylosing spondylitis. Br J Rheumatol 1991;30:330-5.
22. Kennedy LG, Jenkinson TR, Mallorie PA, Whitelock HC, Garrett SL, Calin A. Ankylosing spondylitis: The correlation between a new metrology score and radiology. Br J Rheumatol 1995;34:767-70.
23. Calin A, Mackay K, Brophy S. A new dimension to outcome: Application of the bath ankylosing spondylitis radiology index. J Rheumatol 1999;26:988-92.
24. Dawes PT. Stoke ankylosing spondylitis spinal score. J Rheumatol 1999;26:993-6.
25. Averns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT. Radiological outcome in ankylosing spondylitis: Use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br J Rheumatol 1996;35:373-6.
26. Spoorenberg A, de Vlam K, van der Heijde D, de Klerk E, Dougados M, Mielants H, et al. Radiological scoring methods in ankylosing spondylitis: Reliability and sensitivity to chonge over one year. J Rheumatol 1999;26:997-1002.
27. van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment of fatigue in patients with ankylosing spondylitis: A psychometric analysis. Arthritis Rheum 2002;47:8-16.
28. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-25.
29. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab - A randomised controlled multicentre trial. Lancet 2002;359:1187-93.
30. Dougados M, Caporal R, Doury R, Thiese A, Pattin S, Laffez B, et al. A double blind crossover placebo controlled trial of ximoprofen in AS. J Rheumatol 1989;16:1167-9.
31. Dougados M, Nguyen M, Caporal R, Legeais J, Bouxin-Sauzet A, Pellegrini-Guegoault B, et al. Ximoprofen in ankylosing spondylitis: A double blind placebo controlled dose ranging study. Scand J Rheumatol 1994;23:243-8.
32. Dougados M, Gueguen A, Nakache J-P, Velicitat P, Veys EM, Zeidler H, et al. Ankylosing spondylitis: What is the optimum duration of a clinical study? One year versus a 6 weeks nonsteroidal anti-inflammatory drug trial. Rheumatology (Oxford) 1999;38:235-44.
33. Dougados M, Behier J-M, Jolchine I, Calin A, van der Heijde D, Olivieri I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: A six-week controlled study with comparison against placeba and against a conventional nonsteroidal anti-inflammatory drug. Arthritis Rheum 2001;44:180-5.
34. van Tubergen A, van der Heijde D, Anderson J, Landewé R, Dougados M, Braun J, et al and van der Linden S for the ASAS Working Group Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. Ann Rheum Dis (in press).
35. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;341:1218-26.
36. Amor B, Dougados M, Mijijawa M. Criteres de classification des spondyloarthorpathies. Rev Rhum 1990;57:85-9.
37. van der Linden S, Volkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361-8.
38. Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondyloarthropathy patients. Arthritis Rheum 1994;37:1039-45.
39. Braun J, Bollow M, Sieper J. Radiology and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 1998;24:697-735.
40. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor ontagonist. Arthritis Rheum 1998;41:2196-204.
41. Ahlstrom D, Feltelius N, Nyman R, Hallgren R. Magnetic resonance imaging of sacroiliac joint inflammation. Arthritis Rheum 1990;33:1763-9.
42. Bollow M, Fischer T, Reisshauer H, Backhaus M, Sieper J, Hamm B, et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis - Cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Annals Rheum Dis 2000;59:135-40.
43. Stone M, Salonen D, Iax M, Payne U, Lapp V, Inman R. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001;28:1605-14.
44. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of entheseal pathology in resistant spondylarthropathy. Arthritis Rheum 2001;44:2112-17.
45. Van der Linden S, Volkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
46. Bollow M, Fischer T, Reisshauer H, Backhaus M, Sieper J, Hamm B, et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis - Cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000;59:135-40.
47. van der Heijde D, Boers M, Lassere M. Methodological issues in radiographic scoring methods in rheumatoid arthritis. J Rheumatol 1999;26:726-30.
48. McGonagle D, Matzo-Ortega H, O'Connor P, Gibbon W, Pease C, Reece R, et al. The role of biomechanical factors and HLA-B27 in magnetic resonance imaging-determined bone changes in plantar fascia enthesopathy. Arthritis Rheum 2002;46:489-93.
49. United States Food and Drug Administration. Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA). Food and Drug Administration website. Available at: http//www.fda.gov/cder/guidance/1208fnl.htm. Accessed 1 November 2001.